The system then points to the lack of data as a reason to deny access
No medical interpretation is implied
Treatment with exenatide has been shown to decrease food intake and attenuate food-related neural responses in key regions such as the insula, amygdala, putamen, and orbitofrontal cortex (van Bloemendaal et al., 2014)
adults categorized as overweight or obese, the market for GLP-1s is unlikely to slow down anytime soon
The optimistic scenario assumes: Higher weight-loss efficacy, based on emerging data from trials of AOMs Expanded access to the drug, driving higher uptake assumptions Higher persistency, driven by reduced costs and oral forms of the drug and fewer side effects Lower weight regain after stopping the drug Higher non-weight-loss-related mortality impacts The pessimistic scenario, conversely, considers lower efficacy, lower uptake assumptions, higher and quicker weight regain, and lower non-weight-loss-related mortality impacts